Title: USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS Inventor(s): Dominique BOUREL et al DOCKET NO.: 065691-0433

1/4

ADCC in the presence of effector cells (PBMC) of different blood donors and polyvalent immunoglobulins (Tegeline 500µg/ml).




Fig. 1

ADCC induced by anti-Rhesus D on NK of donors of phenotype CD16 F-F 158




Fig. 2

Title: USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS
Inventor(s): Dominique BOUREL et al DOCKET NO.: 065691-0433

2/4

ADCC induced by anti-Rhesus D on NK of donors of phenotype CD16 V-V 158




Fig. 3

Activation of Jurkat CD16 F-158 by anti-D (T125) expressed in YB2/0 and CHO




Fig. 4

Title: USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS
Inventor(s): Dominique BOUREL et al
DOCKET NO.: 065691-0433

 $3\ /\ 4$ Activation of Jurkat CD16 V-158 by anti-D (T125) expressed in YB2/0 and CHO




Fig. 5

Activation of Jurkat CD16 F-158 by anti-HLA-DR antibodies expressed in CHO and YB2/0.




Fig. 6

Title: USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS Inventor(s): Dominique BOUREL et al DOCKET NO.: 065691-0433

4/4

Activation of Jurkat CD16 V-158 by anti-HLA-DR antibodies expressed in CHO and YB2/0.




Fig. 7